In vitro and in vivo pharmacological characterization of a neuropeptide S tetrabranched derivative

Chiara Ruzza¹, Anna Rizzi¹, Davide Malfacini¹, Alice Pulga¹, Salvatore Pacifico², Severo Salvadori², Claudio Trapella², Rainer K. Reinscheid³, Girolamo Calo¹ & Remo Guerrini²

¹Department of Medical Sciences, Section of Pharmacology and National Institute of Neuroscience, University of Ferrara, 44121, Ferrara, Italy
²Department of Chemical and Pharmaceutical Sciences and LTTA, University of Ferrara, 44121, Ferrara, Italy
³Department of Pharmaceutical Sciences, University of California Irvine, Irvine, California, 92697

Keywords
Calcium mobilization, locomotor activity, mice, neuropeptide S, neuropeptide S receptor, PWT-NPS, righting reflex

Abstract
The peptide welding technology (PWT) is a novel chemical strategy that allows the synthesis of multibranched peptides with high yield, purity, and reproducibility. With this approach, a tetrabranched derivative of neuropeptide S (NPS) has been synthesized and pharmacologically characterized. The in vitro activity of PWT1-NPS has been studied in a calcium mobilization assay. In vivo, PWT1-NPS has been investigated in the locomotor activity (LA) and recovery of the righting reflex (RR) tests. In calcium mobilization studies, PWT1-NPS behaved as full agonist at the mouse NPS receptor (NPSR) being threefold more potent than NPS. The selective NPSR antagonists [tBu-D-Gly]NPS and SHA 68 displayed similar potency values against NPS and PWT1-NPS. In vivo, both NPS (1–100 pmol, i.c.v.) and PWT1-NPS (0.1–100 pmol, i.c.v.) stimulated mouse LA, with PWT1-NPS showing higher potency than NPS. In the RR assay, NPS (100 pmol, i.c.v.) was able to reduce the percentage of mice losing the RR after diazepam administration and their sleep time 5 min after the i.c.v. injection, but it was totally inactive 2 h after the injection. On the contrary, PWT1-NPS (30 pmol, i.c.v.), injected 2 h before diazepam, displayed wake-promoting effects. This PWT1-NPS stimulant effect was no longer evident in mice lacking the NPSR receptor. The PWT1 technology can be successfully applied to the NPS sequence. PWT1-NPS displayed in vitro a pharmacological profile similar to NPS. In vivo PWT1-NPS mimicked NPS effects showing higher potency and long-lasting action.

Abbreviations
ANOVA, analysis of variance; DMF, N,N-dimethylformamide; GPCR, G proteins coupled receptor; HBSS, Hank’s Balanced Salt Solution; HEK293mNPSR, human embryonic kidney 293 cells expressing the murine NPSR; LA, locomotor activity; N/OFQ, nociceptin/orphanin FQ; NKA, neurokinin A; NKB, neurokinin B; NPS, neuropeptide S; NPSR(−/−), NPSR knockout; NPSR(+/+), NPSR wild type; NPSR, NPS receptor; PWT, peptide welding technology; RR, righting reflex; SP, substance P; TFA, trifluoroacetic acid.

Introduction
Neuropeptide S (NPS, human sequence SFRNGVGTGMKKTSFQRAKS) was identified as the endogenous ligand of a previously orphan G proteins coupled receptor (GPCR) now named NPS receptor (NPSR; Xu et al. 2004). In cells expressing the recombinant NPSR, NPS displayed high affinity and stimulated calcium mobilization and cAMP accumulation suggesting Gq and Gs coupling (Reinscheid et al. 2005). In vivo, NPS has been shown to control several biological functions in rodents including stress and anxiety, locomotor...
activity (LA), wakefulness, food intake and gastrointestinal functions, memory processes, and drug abuse (for a review see Guerrini et al. (2010)).

The peptide welding technology (PWT) is a recently developed chemical strategy that allows the synthesis of multibranched peptides with extraordinary high yield, purity, and reproducibility (Guerrini et al. 2014). The PWT has been successfully applied to nociceptin/orphanin FQ (N/OFQ) (Rizzi et al. 2014) and tachykinin peptides (Ruzza et al. 2014). It has been demonstrated that these PWT compounds maintain in vitro the same pharmacological profile of the native peptides but display in vivo higher potency associated with longer lasting action.

In the present work, the PWT derivative of NPS has been synthesized and pharmacologically characterized in vitro, in the calcium mobilization assay performed in human embryonic kidney (HEK 293) cells stably transfected with the murine NPSR (HEK293mNPSR), and in vivo in mice in the LA and in the righting reflex (RR) tests. In the latter test, the selectivity of action of PWT1-NPS has been assessed by using NPSR knockout (NPSR(−/−)) mice.

Materials and Methods

Synthesis of PWT1-NPS

PWT derivative of NPS was prepared by using a convergent synthetic approach and methodology previously applied for the synthesis of PWT derivatives of N/OFQ peptide (Guerrini et al. 2014). Firstly, [Cys21]NPS was synthesized by solid phase method with an automatic solid phase peptide synthesizer Syro II (Biotage, Uppsala, Sweden) using Fmoc/tBu chemistry (Benoiton 2005). The resin 4-(20,40-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-norleucyl-MBHA (Rink amide MBHA resin) was used as a solid support. The resin was treated with 40% piperidine/N,N-dimethylformamide (DMF) and linked with Fmoc-Cys(Trt)-OH by using [O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate] (HATU) as the coupling reagent. The following Fmoc amino acids were sequentially coupled to the growing peptide chain: Fmoc-Ser(tBu)-OH, Fmoc-Lys (Boc)-OH, Fmoc-Ala-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Phe-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Gly-OH, Fmoc-Thr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Val-OH, Fmoc-Gly-OH, Fmoc-Asn (Trt)-OH, Fmoc-Arg(Pmc)-OH, Fmoc-Phe-OH, Fmoc-Ser(tBu)-OH. All the Fmoc amino acids (4 equiv) were coupled to the growing peptide chain by using HATU (4 equiv) in DMF in the presence of an equimolar concentration of 4-methylmorpholine (NMM), and the coupling reaction time was 1 h. To improve the analytical profile of the crude peptide, capping with acetic anhydride (0.5 mol/L/DMF) in the presence of NMM (0.25mol/L/DMF) (3: 1 v/v; 2 mL/0.2 g of resin) was performed at any step. About 40% of Piperidine/DMF was used to remove the Fmoc. The protected peptide-resin was treated with reagent B (Sole and Barany 1992) (trifluoroacetic acid (TFA)/H2O/phenol/triisopropylsilane 88: 5: 5: 2; v:v; 10 mL/0.2 g of resin) for 1.5 h at room temperature. After filtration of the resin, the solvent was concentrated in vacuum and the residue triturated with ether. Crude [Cys21]NPS was purified by preparative reversed-phase high-performance liquid chromatography (HPLC) using a Water Delta Prep 3000 (Meadow Instrumentation, Bristol, WI, USA) system with a Jupiter column C18 (250 × 30 mm, 300 A, 15 μm spherical particle size).

Figure 1. Chemical formula of PWT1-NPS.
The column was perfused at a flow rate of 20 mL/min with a mobile phase containing solvent A (5%, v/v, acetonitrile in 0.1% TFA), and a linear gradient from 0 to 60% of solvent B (60%, v/v, acetonitrile in 0.1% TFA) over 25 min for the elution of peptides. Purified [Cys$^{21}$]NPS was reacted in solution with PWT2 core in a classical thio-Michael reaction using experimental conditions previously optimized for the synthesis of N/OFQ tetrabranched derivatives (Guerrini et al. 2014). Analytical HPLC analyses were performed on a Beckman 116 liquid chromatography equipped with a Beckman 166 diode array detector. Analytical purity of [Cys$^{21}$]NPS and PWT2-NPS was determined using a Luna C$_{18}$ column (4.6 × 100 mm, 3 μm particle size) with the above solvent system (solvents A and B) programed at a flow rate of 0.5 mL/min using a linear gradient from 0% to 600% B over 25 min. Final product showed ≥95% purity when monitored at 220 nm. Molecular weight of PWT1-NPS was in accord with the expected molecular formula. PWT1-NPS chemical structure is shown in Fig. 1.

**Calcium mobilization assay**

HEK293$_{mNPSR}$ cells were maintained in Dulbecco’s Medium (DMEM) supplemented with 10% fetal bovine serum, 2 mmol/L L-glutamine, and 100 mg/L hygromycin. The cells were cultured at 37°C in 5% CO$_2$-humidified air and seeded at a density of 50,000 cells/well into poly-D-Lysine coated 96-well black, clear-bottom plates. The following day, the cells were incubated with a medium supplemented with 2.5 mmol/L probenecid, 3 μmol/L calcium-sensitive fluorescent dye Fluo-4 AM, and 0.01% pluronic acid, for 30 min at 37°C. After that time the loading solution was aspirated and 100 μL/well of assay buffer Hank's Balanced Salt Solution (HBSS) supplemented with 20 mmol/L 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 2.5 mmol/L probenecid, and 500 μmol/L Brilliant Black (Sigma-Aldrich, St. Louis, MO) was added. Concentrated solutions (1 mmol/L) of NPS, [Cys$^{21}$]NPS-NH$_2$, PWT1-NPS, and [Bu-D-Gly$^2$]NPS were made in bidistilled water. SHA 68 was solubilized in dimethyl sulfoxide (DMSO) (10 mmol/L). Serial dilutions were carried out in HBSS/HEPES (20 mmol/L) buffer (containing 0.02% bovine serum albumin (BSA) fraction V). After placing both plates (cell culture and compound plate) into the FlexStation II, fluorescence changes were measured at 37°C. Online additions were carried out in a volume of 50 μL/well. Using previously validated protocols (Guerrini et al. 2009b; Ruzza et al. 2010), in antagonist-type experiments the compounds under study were preincubated for 24 min before agonist addition. To facilitate drug diffusion into the wells in antagonist type experiments, three cycles of mixing (25 μL from each well moved up and down three times) were performed immediately after antagonist injection to the wells. Maximum change in fluorescence, expressed in percent of baseline fluorescence, was used to determine agonist response.

**In vivo studies**

All experimental procedures adopted for in vivo studies were as humane as possible and complied with the European Communities Council directives (2010/63/EU) and national regulations (D.L. 116/92). The present study was approved by the Ethical Committee for the Use of Laboratory Animals (CEASA) of the University of Ferrara and by the Italian Ministry of Health (authorization number 75-76/2013-B). This research was reported following the ARRIVE guidelines (Kilkenny et al. 2010) and complies with the prevailing standards of animal welfare embodied in UK laws governing animal experimentation. Male CD-1 mice (weight 28–35 g; Harlan, Udine, Italy) and male NPSR($^{+/−}$) and NPSR($^{+/+}$) mice congenic to CD-1 strain (8 weeks old, bred in animal facility of the Section of Pharmacology of the University of Ferrara) were used in a total number of 146. They were housed in 267 × 207 × 140 mm cages (Tecniplast, Buguggiate, Italy), five mice/cage, under standard conditions (22°C, 55% humidity, 12 h light–dark cycle, lights on 7.00 AM) with food (standard diet; Mucedola, Settimo Milanese, Italy), and water ad libitum for at least 15 days before experiments began. Each cage was provided with a mouse red house (Tecniplast, Buguggiate, Italy) and nesting materials. Each animal was used only once. NPS and PWT1-NPS were injected intracerebroventricularly (i.c.v.). I.c.v. injections (2 μL per mouse) were given under light isoflurane anesthesia, into the left ventricle according to the procedure described by Laursen and Belknap (1986) and routinely adopted in our laboratory (Rizzi et al. 2008).

**LA assay**

Experiments were performed during the light cycle (between 09.00 and 13.00) according to previously reported procedures (Guerrini et al. 2009b). For these experiments, the ANY-maze video tracking system was used (Ugo Basile, Varese, Italy; application version 4.52c Beta). Mice were positioned in a square plastic cage (40 cm × 40 cm), one mouse per cage. Four mice were monitored in parallel. Mouse’s horizontal activity was monitored by a camera, while vertical activity was measured by an infrared beam array. Animals’ locomotion was recorded for 120 min. The parameters measured were cumulative distance travelled (total distance in m that the animal travelled during the test), immobility time (the animal is considered immobile when 90% of it remains...
in the same place for a minimum of 2.5 sec), and the number of rearings (the number of beam breaks due to vertical movements; this input is triggered when the beam is interrupted for a minimum of 200 msec). NPS (1–100 pmol) and PWT1-NPS (0.1–100 pmol) were injected i.c.v. 15 min before starting the test.

**RR assay**

This assay was performed according to the procedures previously described in detail (Rizzi et al. 2008). Briefly, mice were given an i.p. injection of diazepam (15 mg/kg; Sigma-Aldrich). When the animals lost the RR, they were placed in a plastic cage and the time was recorded by an expert observer blind to drug treatments. Animals were judged to have regained the RR response when they could right themselves three times within 30 sec. Sleep time is defined as the amount of time between the loss and regaining of the RR and was rounded to the nearest minute. NPS (100 pmol) and PWT1-NPS (30 pmol) were injected i.c.v. 5 min, 2, and 4 h before diazepam administration. These time points were selected because previous studies demonstrated NPS effectiveness at 5 min (e.g., Rizzi et al. 2008) and unpublished results indicated lack of effect of NPS after 2 h from injection. In the experiments performed with NPSR(+/-) and NPSR(-/-) mice, PWT1-NPS was injected 2 h before diazepam.

**Drugs and reagents**

NPS was synthesized according to published methods (Guerrini et al. 2009b) using Fmoc/tBu chemistry with a SYRO XP multiple peptide synthesizer (MultiSynTech, Witten, Germany). Crude peptide was purified by preparative reversed-phase HPLC and the purity checked by analytical HPLC and mass spectrometry using an ESI Micromass ZMD-2000 mass spectrometer (Waters Corporation, Milford, MA). SHA 68 was synthesized using the procedures described by Okamura et al. (2008). For the in vitro studies NPS, PWT1-NPS, and [tBu-D-Gly⁵]NPS were dissolved in water, while SHA 68 was dissolved in DMSO. For the in vivo experiments, the vehicle used for injecting NPS and PWT1-NPS was saline.

**Data analysis and terminology**

The pharmacological terminology adopted in this paper is consistent with IUPHAR recommendations (Neubig et al. 2003). In vitro data were expressed as mean ± SEM of at least four independent experiments made in duplicate. Maximum change in fluorescence, expressed as percent over the baseline fluorescence, was used to determine agonist response. Nonlinear regression analysis using GraphPad Prism software (v.5.0; GraphPad, La Jolla, CA) allowed logistic interactive fitting of the resultant responses and the calculation of agonist potencies and maximal effects. Agonist potencies were given as pEC₅₀ (the negative logarithm to base 10 of the molar concentration of an agonist that produces 50% of the maximal possible effect). [tBu-D-Gly⁵]NPS and SHA 68 antagonist properties were evaluated in inhibition response curve experiments versus a fixed concentration of NPS and PWT1-NPS approximately corresponding to its EC₈₀; the antagonist potency was expressed as pKᵦ derived from the following equation:

\[ K_A = \frac{IC_{50}}{[2 + ([A]/EC_{50})^n]^{1/n} - 1} \]

where IC₅₀ is the concentration of antagonist that produces 50% inhibition of the agonist response, [A] is the concentration of agonist, EC₅₀ is the concentration of agonist producing a 50% maximal response, and n is the Hill coefficient of the concentration response curve to the agonist (Kenakin 2004). In vivo data are expressed as mean ± sem of n animals. Data were analyzed using one-way analysis of variance (ANOVA) followed by the Dunnett’s post hoc test or two-way ANOVA followed by the Bonferroni’s post hoc test, as specified in figure legends. Differences were considered statistically significant when \( P < 0.05 \).

**Results**

**Calcium mobilization assay**

In HEK293mNPSR cells, NPS increased intracellular calcium levels in a concentration-dependent manner with pEC₅₀ and \( E_{\text{max}} \) values of 8.55 (8.09–9.00) and 417 ± 34% over the basal levels, respectively. As shown in Figure 2, PWT1-NPS stimulated calcium mobilization.
producing similar maximal effects as the natural peptide but being threefold more potent (pEC_{50} = 8.99 [8.68–9.31]). The stimulatory effects produced by NPS and PWT1-NPS were challenged with the selective NPSR antagonists [\textsuperscript{t}Bu-D-Gly\textsuperscript{5}]NPS and SHA 68 in inhibition response experiments. [\textsuperscript{t}Bu-D-Gly\textsuperscript{5}]NPS inhibited the stimulatory effects evoked by NPS (30 nM) and PWT1-NPS (30 nM) with similar potency values (pK_{B} 6.89 [6.57–7.21] vs. NPS and 6.88 [6.41–7.35] vs. PWT1-NPS, Figure 3A and B). Similarly, the nonpeptide NPSR antagonist SHA 68 blocked in a concentration-dependent manner the stimulant action of NPS and PWT1-NPS with similar potency (pK_{B} = 7.84 [6.97–8.71] and 7.99 [7.76–8.22], respectively, Fig. 3C and D).

**LA test**

In the LA test, mouse horizontal and vertical activity were measured for 2 h after i.c.v. injection. Saline-treated mice explore the LA arena especially during the first hour of the experiment, while their LA resulted widely reduced during the second hour of test. As shown in Figure 4, NPS (1–100 pmol) evoked, in a dose-dependent manner, a robust stimulatory effect on mouse LA by increasing the cumulative distance travelled by the animals and their number of rearings, and reducing the total immobility time. NPS was active from the 10 pmol dose and this effect lasted approximately for 1 h after the injection. During the second hour of the test, only the higher NPS dose (100 pmol) was able to produce statistically significant effects. PWT1-NPS (0.1–100 pmol) increased the distance travelled by the animals and their number of rearings, and reduced the total immobility time from the dose of 1 pmol, resulting in this test 10-fold more potent than NPS. Similar to NPS, the stimulatory effects evoked by PWT1-NPS were no longer evident during the second hour of the test. Only the highest dose of PWT1-NPS used (100 pmol) was able to reduce, in a statistically significant manner, the immobility time of mice during the second hour (Fig. 5).

**Recovery of RR**

As demonstrated in previous studies, in the RR, 0.1 nmol NPS, injected i.c.v. 5 min before diazepam, was able to reduce the percentage of mice losing the RR...
and to reduce the sleep time of those mice responding to diazepam. This effect of NPS was no longer evident when NPS was injected 2 h before diazepam administration. On the contrary, PWT1-NPS (0.03 pmol, i.c.v.), given 5 min before diazepam, did not change the percentage of mice losing the RR but was able to significantly reduce the sleep time induced by diazepam. When PWT1-NPS was injected 2 h before diazepam administration it reduced both the percentage of mice losing the RR and the sleep time of those mice responding to diazepam (Fig. 6A and B). PWT1-NPS was not able to produce any statistically significant effects 4 h after the

Figure 4. Mouse locomotor activity test. Dose–response curve to NPS (1–100 pmol, i.c.v., 15 min before starting the test). Time course of the distance travelled is shown in (A). According to one-way ANOVA followed by the Dunnett’s post hoc test, NPS elicited a statistically significant effect on the cumulative distance travelled ($F_{(3,27)} = 17.79$ 0–60 min; $F_{(3,27)} = 5.42$ 60–120 min, B), total time immobile ($F_{(3,27)} = 12.57$ 0–60 min; $F_{(3,27)} = 6.03$ 60–120 min, C), and number of rearings ($F_{(3,27)} = 16.59$ 0–60 min; $F_{(3,27)} = 3.96$ 60–120 min, D). Data are mean ± SEM of eight mice per group, *$P < 0.05$ vs. saline.

Figure 5. Mouse locomotor activity test. Dose–response curve to PWT1-NPS (0.1–100 pmol, i.c.v., 15 min before starting the test). Time course of the distance travelled is shown in panel A. According to one-way ANOVA followed by the Dunnett’s post hoc test, PWT1-NPS elicited a statistically significant effect on the cumulative distance travelled ($F_{(4,32)} = 7.95$ 0–60 min, B), total time immobile ($F_{(4,32)} = 13.49$ 0–60 min; $F_{(4,32)} = 2.70$ 60–120 min, C), and number of rearings ($F_{(4,32)} = 12.20$ 0–60 min, D). Data are mean ± SEM of 7–8 mice per group, *$P < 0.05$ vs. saline.
injection (data not shown). Under the present experimental conditions, no differences were measured between NPSR(+/-) and NPSR(-/-) mice in terms of sensitivity to diazepam. PWT1-NPS (0.03 pmol, i.c.v., 2 h of pretreatment) elicited a robust wake-promoting effect in NPSR(+/-) mice; this action of PWT1-NPS was no longer evident in mice lacking the NPSR receptor (Fig. 6C and D).

**Discussion and Conclusions**

In the present study, the pharmacological profile of a tetrabranched derivative of NPS generated with the PWT has been investigated in vitro and in vivo.

The PWT is an innovative chemical strategy that allows the efficient synthesis of multibranched peptides. The chemical details of the PWT have been recently described (Guerrini et al. 2014) and PWT derivatives of N/OFQ (Rizzi et al. 2014) and tachykinins (Ruzza et al. 2014) have been generated and pharmacologically characterized. This technology is based on the extremely chemoselective reaction between a maleimide functionalized central core and a Cys residue that must be introduced into the peptide sequence. This attachment point is crucial for maintaining biological activity. Since previous structure activity studies indicate that the N-terminal region of NPS plays a crucial role for bioactivity (Bernier et al. 2006; Roth et al. 2006), the Cys residue has been added at the C terminus of NPS and [Cys21]NPS has been used for generating PWT1-NPS.

In the calcium mobilization assay, NPS produced a concentration-dependent increase in intracellular calcium levels, similar to previously reported data (Camarda et al. 2008a,b, 2009; Guerrini et al. 2009a,b). PWT1-NPS mimicked the stimulatory effect of NPS displaying similar maximal effects. Thus, PWT1-NPS behaved as a full NPSR agonist. Comparable results have been obtained with PWT derivatives of N/OFQ (Rizzi et al. 2014) and tachykinins (Ruzza et al. 2014). Thus, the PWT has no impact on the ability of the peptide sequence to bind and fully activate the receptor. As far as potency is concerned, PWT1-NPS resulted in the calcium mobilization assay threefold more potent than NPS. Interestingly, this is the first PWT derivative, so far evaluated, that displayed in this assay higher potency than the natural sequence. In fact, in this test, N/OFQ, SP, and NK-A were more potent than their PWT derivatives, while NK-B and PWT2-NKB displayed similar potency values (Rizzi et al. 2014; Ruzza et al. 2014). As discussed in detail in Rizzi et al. (2014) and in Ruzza et al. (2014), this loss of potency of PWT derivatives in the calcium mobilization assay has been ascribed to the fact that PWT derivatives of N/OFQ, SP,
and NKA need longer time to occupy and fully activate their receptors than the natural peptide sequences. This slow interacting kinetic is not compatible to the rapid and transient nature of the calcium spike. As a consequence, the calcium assay tends to underestimate the potency of slow interacting ligands (Charlton and Vauquelin 2010). Based on these considerations, it can be speculated that the kinetic of interaction with NPSR is similar for NPS and PWT1-NPS and is probably faster than that of the other PWT derivatives so far characterized. Of note, both the peptidic NPS antagonist [Bu-D-Gly]NPS (Guerrini et al. 2009a) and the nonpeptidic NPSR antagonist SHA 68 (Okamura et al. 2008) inhibited the stimulant effects of NPS and PWT1-NPS with the same potency, demonstrating that the mechanisms by which PWT1-NPS elicited the increase in intracellular calcium levels is the activation of NPSR.

In vivo, PWT1-NPS has been tested in the LA and in the RR. Several studies demonstrated that NPS increases mouse LA (Xu et al. 2004; Rizzi et al. 2008; Castro et al. 2009; Guerrini et al. 2009b; Paneda et al. 2009) and produces wake-promoting effects in the RR test (Rizzi et al. 2008; Camarda et al. 2009; Kushikata et al. 2011). Both knockout (Camarda et al. 2009; Duangdao et al. 2009; Zhu et al. 2010; Fendt et al. 2011; Ruzza et al. 2012a) and antagonism (Okamura et al. 2008; Camarda et al. 2009; Ruzza et al. 2010, 2012b; Kushikata et al. 2011) studies demonstrated that the stimulant and wake-promoting actions of NPS are due to the selective activation of NPSR. In line with previous findings, in the present study NPS increased mouse LA. PWT1-NPS mimicked NPS stimulant action showing 10-fold higher potency. In fact the lower dose of NPS producing statistically significant effects was 100 pmol while that of PWT1-NPS was 10 pmol. In the RR test, NPS 100 pmol evoked wake-promoting effects. PWT1-NPS, at the dose of 30 pmol, produced in the RR similar effects as those elicited by NPS. Thus, in mice, PWT1-NPS was able to elicit the same effects of NPS but being 3–10 more potent.

As far as the duration of action is concerned, no differences were measured in the LA assay between NPS and PWT1-NPS. Of note, mouse LA strongly decreases during the time course of the experiment. This is probably due to the mouse habituation to the open field. This phenomenon might be a bias for the interpretation of these results. In fact, under these experimental conditions, it is not clear if the lack of effects of NPS and PWT1-NPS during the second hour of the assay is imputable to the inactivation of the peptides or to a progressive reduction in animal sensitivity to their stimulant action. Considering this, LA is probably not the best assay to investigate the effects of long-lasting stimulant drugs. Interestingly, when tested in the RR test, PWT1-NPS displayed longer duration of action compared to NPS. In fact, at equieffective doses NPS and PWT1-NPS elicited similar and robust wake-promoting effects after 5 min from injection. However, PWT1-NPS, injected 2 h before diazepam, was still able to evoke statistically significant wake-promoting effects, while NPS resulted totally inactive at this time point. Thus, PWT1-NPS emerged in vivo not only more potent than NPS but also longer lasting. Similar findings were described for PWT derivatives of both N/OFQ (Rizzi et al. 2014) and SP (Ruzza et al. 2014). The available evidence suggests that these features may derive from an increased stability to enzymatic degradation and/or longer lasting binding to the receptor. In fact, an increased stability to enzymatic degradation has been demonstrated for multibranched derivatives of N/OFQ, enkephalins, and neurotensin (Bracci et al. 2003). No data are so far available regarding NPS susceptibility to enzymatic degradation. Therefore, future studies investigating the metabolic stability of NPS and PWT-NPS will be of high interest and utility. It is also possible that longer lasting binding to NPSR may contribute to increase the in vivo duration of action of PWT1-NPS. In fact, multivalent ligands, via multiple molecular mechanisms (Gestwicki et al. 2002), may display long-lasting target binding and this feature might be crucial for prolonging in vivo drug action (Vauquelin and Charlton 2010). In this regard, it is worthy of note that PWT derivatives of N/OFQ (Rizzi et al. 2014) and of SP (Ruzza et al. 2014) are less sensitive to wash in organ bath experiments compared to the natural peptide sequences. Unfortunately, similar kind of experiments could not be performed with PWT1-NPS since NPS-sensitive preparations useful for bioassay experiments are not described yet. However, it should be underlined that these considerations are rather speculative and well grounded hypotheses can be proposed only after direct investigation of NPS and PWT1-NPS metabolic stability and receptor-binding features. Available evidence suggests that increased in vivo potency associated with longer duration of action is a common feature of PWT derivatives. However, it is worth of note that quantitatively the amount of differences in potency and duration of action between the native peptide and its PWT derivative strongly depend on peptide sequence. In particular, PWT derivatives of N/OFQ resulted up to 40-fold more potent than N/OFQ and displayed extremely longer duration of action that is, from ~20 min for N/OFQ up to 24 h (Rizzi et al. 2014). PWT2-SP was in vivo 3- to 10-fold more potent than SP and displayed approximately fourfold longer duration of action (from ~5 min for SP to ~20 min for PWT2-SP) (Ruzza et al. 2014). The in vivo behavior of PWT1-NPS is close to that of PWT2-SP. The reason for these sequence-dependent effects of PWT derivatives is at present unknown. It will be useful to...
apply this technology to several different peptide sequences to understand if these differences are related, for instance, to different susceptibility to proteases and/or different mechanisms by which the peptides bind and activate their receptors.

While the PWT increased the potency and the duration of action of NPS in vivo, it did not affect the peptide selectivity for NPSR. In fact, PWT1-NPS failed to produce wake-promoting effects in mice lacking the NPSR protein. This result demonstrated that the mechanism by which PWT1-NPS exerted its wake-promoting effect is the selective activation of NPSR.

In conclusion, the present study extended the use of the PWT to the NPS sequence. PWT1-NPS mimicked NPS actions in vitro and behaved in vivo as a selective, potent, and long-lasting NPSR agonist. Thus the present work, together with previous findings (Rizzi et al. 2014; Ruzza et al. 2014), demonstrated that PWT is an innovative and efficient strategy to generate interesting peptide receptors ligands. PWT1-NPS can be proposed as an innovative tool for the study of the pharmacology and the neurobiology of the NPS/NPSR system particularly for investigating those conditions in which a prolonged activation of the NPSR is desirable, that is, panic and anxiety disorders (Xu et al. 2004; Leonard et al. 2008; Rizzi et al. 2008; Pulga et al. 2012) and possibly memory impairment (Han et al. 2009, 2013; Zhao et al. 2010; Okamura et al. 2011).

Acknowledgements
This work was supported by funds from UFPeptides s.r.l.

Disclosures
G. C., S. S., and R. G. are inventors of the patent application (EP13162532.9) focused on PWT technology and are founders of the University of Ferrara spin off company UFPeptides s.r.l. the assignee of such patent application.

References
Benoiton NL (2005). Solid-phase synthesis. In Chemistry of peptide synthesis, edn: Taylor & Francis, Oxford, UK. pp 125–154.
Bernier V, Stocco R, Bogusky MJ, Joyce JG, Parachoniak C, Grenier K, et al. (2006). Structure-function relationships in the neuropeptide S receptor: molecular consequences of the asthma-associated mutation N107I. J Biol Chem 281: 24704–24712.
Bracci L, Falciani C, Lelli B, Lozzi L, Runci Y, Pini A, et al. (2003). Synthetic peptides in the form of dendrimers become resistant to protease activity. J Biol Chem 278: 46590–46595.
Camarda V, Trapella C, Calo G, Guerrini R, Rizzi A, Ruzza C, et al. (2008a). Structure-activity study at positions 3 and 4 of human neuropeptide S. Bioorg Med Chem 16: 8841–8845.
Camarda V, Trapella C, Calo G, Guerrini R, Rizzi A, Ruzza C, et al. (2008b). Synthesis and biological activity of human neuropeptide S analogues modified in position 2. J Med Chem 51: 655–658.
Camarda V, Rizzi A, Ruzza C, Zucchini S, Marzola G, Marzola E, et al. (2009). In vitro and in vivo pharmacological characterization of the neuropeptide S receptor antagonist [D-Cys (Bu)5]neuropeptide S. J Pharmacol Exp Ther 328: 549–555.
Castro AA, Moretti M, Casagrande TS, Martinello C, Petronilho F, Steckert AV, et al. (2009). Neuropeptide S produces hyperlocomotion and prevents oxidative stress damage in the mouse brain: a comparative study with amphetamine and diazepam. Pharmacol Biochem Behav 91: 636–642.
Charlton SJ, Vauquelin G (2010). Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays. Br J Pharmacol 161: 1250–1265.
Duangdao DM, Clark SD, Okamura N, Reinsheid RK (2009). Behavioral phenotyping of neuropeptide S receptor knockout mice. Behav Brain Res 205: 1–9.
Fendt M, Buchi M, Burki H, Imobersteg S, Ricoux B, Suply T, et al. (2011). Neuropeptide S receptor deficiency modulates spontaneous locomotor activity and the acoustic startle response. Behav Brain Res 217: 1–9.
Gestwicki JE, Cairo CW, Strong LE, Oetjen KA, Kiessling LL (2002). Influencing receptor-ligand binding mechanisms with multivalent ligand architecture. J Am Chem Soc 124: 14922–14933.
Guerrini R, Camarda V, Trapella C, Calo G, Rizzi A, Ruzza C, et al. (2009a). Further studies at neuropeptide S position 5: discovery of novel neuropeptide S receptor antagonists. J Med Chem 52: 4068–4071.
Guerrini R, Camarda V, Trapella C, Calo G, Rizzi A, Ruzza C, et al. (2009b). Synthesis and biological activity of human neuropeptide S analogues modified in position 5: identification of potent and pure neuropeptide S receptor antagonists. J Med Chem 52: 524–529.
Guerrini R, Salvadori S, Rizzi A, Regoli D, Calo G (2010). Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor. Med Res Rev 30: 751–777.
Guerrini R, Marzola E, Trapella C, Pela M, Molinari S, Cerlesi MC, et al. (2014). A novel and facile synthesis of tetra branched derivatives of nociceptin/orphanin FQ. Bioorg Med Chem 22: 3703–3712.
Han RW, Yin XQ, Chang M, Peng YL, Li W, Wang R (2009). Neuropeptide S facilitates spatial memory and mitigates spatial memory impairment induced by N-methyl-D-aspartate receptor antagonist in mice. Neurosci Lett 455: 74–77.
Han RW, Zhang RS, Xu HJ, Chang M, Peng YL, Wang R (2013). Neuropeptide S enhances memory and mitigates memory impairment induced by MK801, scopolamine or Abeta(1-40) in mice novel object and object location recognition tasks. Neuropharmacology 70: 261–267.

Kenakin T (2004). A pharmacology primer: theory, application and methods. Elsevier, Amsterdam, London.

Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, Group NCRRGW (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577–1579.

Kushikata T, Yoshida H, Kudo M, Salvadori S, Calo G, Hirot a K (2011). The effects of neuropeptide S on general anesthesia in rats. Anest Analg 112: 845–849.

Laursen SE, Belknap JK (1986). Intracerebroventricular injections in mice. Some methodological refinements. J Pharmacol Meth 16: 355–357.

Leonard SK, Dwyer JM, Sukoff Rizzo SJ, Platt B, Logue SF, Neal SJ, et al. (2008). Pharmacology of neuropeptide S in mice: therapeutic relevance to anxiety disorders. Psychopharmacology 197: 601–611.

Neubig RR, Spedding M, Kenakin T, Christopoulos A (2003). International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 55: 597–606.

Okamura N, Habay SA, Zeng J, Chamberlin AR, Reinscheid RK (2008). Synthesis and pharmacological in vitro and in vivo profile of 3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68), a selective antagonist of the neuropeptide S receptor. J Pharmacol Exp Ther 325: 893–901.

Okamura N, Garau C, Duangdao DM, Clark SD, Jungling K, Pape HC, et al. (2011). Neuropeptide S enhances memory during the consolidation phase and interacts with noradrenergic systems in the brain. Neuropsychopharmacology 36: 744–752.

Paneda C, Huitron-Resendiz S, Frago LM, Chowen JA, Picetti R, de Lecea L, et al. (2009). Neuropeptide S reinstates cocaine-seeking behavior and increases locomotor activity through corticotropin-releasing factor receptor 1 in mice. J Neurosci 29: 4155–4161.

Pulga A, Rizzi A, Rizzi A, Guerrini R, Calo G (2012). Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze. Eur J Neurosci 36: 3531–3537.

Reinscheid RK, Xu YL, Okamura N, Zeng J, Chung S, Pai R, et al. (2005). Pharmacological characterization of human and murine neuropeptide s receptor variants. J Pharmacol Exp Ther 315: 1338–1345.

Rizzi A, Vergura R, Marzola G, Ruzza C, Guerrini R, Salvadori S, et al. (2008). Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice. Br J Pharmacol 154: 471–479.

Rizzi A, Malfacini D, Cerlesi MC, Ruzza C, Marzola E, Bird MF, et al. (2014). In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives. Br J Pharmacol 171: 4138–4153.

Roth AL, Marzola E, Rizzi A, Arduin M, Trapella C, Corti C, et al. (2006). Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation. J Biol Chem 281: 20809–20816.

Ruzza C, Rizzi A, Trapella C, Pela M, Camarda V, Ruggieri V, et al. (2010). Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. Peptides 31: 915–925.

Ruzza C, Pulga A, Rizzi A, Marzola G, Guerrini R, Calo G (2012a). Behavioural phenotypic characterization of CD-1 mice lacking the neuropeptide S receptor. Neuropharmacology 62: 1999–2009.

Ruzza C, Rizzi A, Camarda V, Pulga A, Marzola G, Filferro M, et al. (2012b). [‘Bu-D-Gly’]NPS, a pure and potent antagonist of the neuropeptide S receptor: in vitro and in vivo studies. Peptides 34: 404–411.

Ruzza C, Rizzi A, Malfacini D, Cerlesi MC, Ferrari F, Marzola E, et al. (2014). Pharmacological characterization of tachykinin tetrabranched derivatives. Br J Pharmacol 171: 4125–4137.

Sole NA, Barany G (1992). Optimization of solid-phase synthesis of [Ala8]-dynorphin. J Org Chem 57: 5399–5403.

Vauquelin G, Charlton SJ (2010). Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br J Pharmacol 161: 488–508.

Xu YL, Reinscheid RK, Huitron-Resendiz S, Clark SD, Wang Z, Lin SH, et al. (2004). Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron 43: 487–497.

Zhao Z, Huang L, Wu H, Li Y, Zhang L, Yin Y, et al. (2010). Neuropeptide S mitigates spatial memory impairment induced by rapid eye movement sleep deprivation in rats. Neuroreport 21: 623–628.

Zhu H, Mingler MK, McBride ML, Murphy AJ, Valenzuela DM, Yanopoulos GD, et al. (2010). Abnormal response to stress and impaired NPS-induced hyperlocomotion, anxiolytic effect and corticosterone increase in mice lacking NPSR1. Psychoneuroendocrinology 35: 1119–1132.